FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jan Jacques Michiels

Research Profile

Disorders

Chemicals & Drugs

Phenomena

Bleeding Time

Anatomy

Co-author Network

Publications

TOP 3
Reinhard Schneppenheim; Jan Jacques Michiels; Tobias Obser; Florian Oyen; Antje Pieconka; Sonja Schneppenheim; Kerstin Will; Barbara Zieger; Ulrich Budde
A cluster of mutations in the D3 domain of von Willebrand factor correlates with a distinct subgroup of von Willebrand disease: type 2A/IIE.
Christoph Sucker; Jan Jacques Michiels; Rainer B Zotz
Causes, etiology and diagnosis of acquired von Willebrand disease: a prospective diagnostic workup to establish the most effective therapeutic strategies.
Jan Jacques Michiels; Huub H D M van Vliet; Zwi Berneman; Wilfried Schroyens; Alain Gadisseur
Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jan Jacques Michiels (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Reinhard Schneppenheim; Jan Jacques Michiels; Tobias Obser; Florian Oyen; Antje Pieconka; Sonja Schneppenheim; Kerstin Will; Barbara Zieger; Ulrich Budde
A cluster of mutations in the D3 domain of von Willebrand factor correlates with a distinct subgroup of von Willebrand disease: type 2A/IIE.
Blood 2010;115(23):4894-901.
2009: Christoph Sucker; Jan Jacques Michiels; Rainer B Zotz
Causes, etiology and diagnosis of acquired von Willebrand disease: a prospective diagnostic workup to establish the most effective therapeutic strategies.
Acta haematologica 2009;121(2-3):177-82.
2009: Jan Jacques Michiels; Huub H D M van Vliet; Zwi Berneman; Wilfried Schroyens; Alain Gadisseur
Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Acta haematologica 2009;121(2-3):167-76.
2009: Jan Jacques Michiels; Huub H D M van Vliet
Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
Acta haematologica 2009;121(2-3):154-66.
2009: Alain Gadisseur; Marc van der Planken; Wilfried Schroyens; Zwi Berneman; Jan Jacques Michiels
Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
Acta haematologica 2009;121(2-3):145-53.
2009: Alain Gadisseur; Zwi Berneman; Wilfried Schroyens; Jan Jacques Michiels
Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Acta haematologica 2009;121(2-3):128-38.
2009: Jan Jacques Michiels; Alain Gadisseur; Inge Vangenegten; Wilfried Schroyens; Zwi Berneman
Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
Acta haematologica 2009;121(2-3):119-27.
2009: Jan Jacques Michiels; Alain Gadisseur; Marc van der Planken; Wilfried Schroyens; Zwi Berneman
Laboratory and molecular characteristics of recessive von Willebrand disease type 2C (2A subtype IIC) of variable severity due to homozygous or double heterozygous mutations in the D1 and D2 domains.
Acta haematologica 2009;121(2-3):111-8.
2009: Jan Jacques Michiels; Zwi Berneman; Alain Gadisseur; Marc van der Planken; Wilfried Schroyens; Huub H D M van Vliet
Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1.
Acta haematologica 2009;121(2-3):85-97.
2009: Alain Gadisseur; Cedric Hermans; Zwi Berneman; Wilfried Schroyens; Hans Deckmyn; Jan Jacques Michiels
Laboratory diagnosis and molecular classification of von Willebrand disease.
Acta haematologica 2009;121(2-3):71-84.
2008: Huub H D M van Vliet; Mies C Kappers-Klunne; Frank W G Leebeek; Jan Jacques Michiels
PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
Thrombosis and haemostasis 2008;100(3):462-8.
2007: Jan Jacques Michiels; S Commandeur; G J Hoogenboom; J J Wegman; L Scholten; R H van Rijssel; Hendrik De Raeve
JAK2(V617F) positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature.
Annals of hematology 2007;86(11):793-800.
2007: Jan Jacques Michiels; Hendrik De Raeve; Konnie Hebeda; King H Lam; Zwi Berneman; Wilfried Schroyens; Jiri Schwarz
WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.
Leukemia research 2007;31(8):1031-8.
2007: Jan Jacques Michiels; Meinrad Gawaz
Preface: platelets in inflammation and atherothrombosis.
Seminars in thrombosis and hemostasis 2007;33(2):119-22.
2007: Jan Jacques Michiels; Z Bernema; Dirk R Van Bockstaele; Hendrik De Raeve; Wilfried Schroyens
Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Pathologie-biologie 2007;55(2):92-104.
2007: Jan Jacques Michiels; Huub H D M van Vliet; Zwi Berneman; Alain Gadisseur; Marc van der Planken; Wilfried Schroyens; Ann van der Velden; Ulrich Budde
Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2007;13(1):14-34.
2006: Jan Jacques Michiels; Zwi Berneman; Wilfried Schroyens; Peter J Koudstaal; Jan Lindemans; H A M Neumann; Huub H D M van Vliet
Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
Platelets 2006;17(8):528-44.
2006: Jan Jacques Michiels; Alain Gadisseur; Marc van der Planken; Wilfried Schroyens; Marianne De Maeseneer; Jan T Hermsen; Paul H Trienekens; Henk Hoogsteden; Peter M T Pattynama
Different accuracies of rapid enzyme-linked immunosorbent, turbidimetric, and agglutination D-dimer assays for thrombosis exclusion: impact on diagnostic work-ups of outpatients with suspected deep vein thrombosis and pulmonary embolism.
Seminars in thrombosis and hemostasis 2006;32(7):678-93.
2006: Jan Jacques Michiels; Zwi Berneman; Alain Gadisseur; Marc van der Planken; Wilfried Schroyens; Ann van de Velde; Huub H D M van Vliet
Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2006;12(4):397-420.
2006: Jan Jacques Michiels
The use of aspirin and clinical implications in essential thrombocythemia.
Seminars in thrombosis and hemostasis 2006;32(6):646-8.
2006: Jan Jacques Michiels; Alain Gadisseur; Marc van der Planken; Wilfried Schroyens; Ann van de Velden; Zwi Berneman
Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
Seminars in thrombosis and hemostasis 2006;32(6):636-45.
2006: Jan Jacques Michiels; Zwi Berneman; Wilfried Schroyens; Guido Finazzi; Ulrich Budde; Huub H D M van Vliet
The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Seminars in thrombosis and hemostasis 2006;32(6):589-604.
2006: Jan Jacques Michiels; Zwi Berneman; Alain Gadisseur; Marc van der Planken; Wilfried Schroyens; Ulrich Budde; Huub H D M van Vliet
Immune-mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: therapeutic implications.
Seminars in thrombosis and hemostasis 2006;32(6):577-88.
2006: Jan Jacques Michiels; Zwi Berneman; Alain Gadisseur; Marc van der Planken; Wilfried Schroyens; Ann van de Velde; Huub H D M van Vliet
Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2006;12(3):277-95.
2006: Jan Jacques Michiels; Hendrik De Raeve; Zwi Berneman; Dirk R Van Bockstaele; Konnie Hebeda; King Lam; Wilfried Schroyens
The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Seminars in thrombosis and hemostasis 2006;32(4 Pt 2):307-40.
2006: Jan Jacques Michiels; Zwi Berneman; Dirk R Van Bockstaele; Marc van der Planken; Hendrik De Raeve; Wilfried Schroyens
Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Seminars in thrombosis and hemostasis 2006;32(3):174-207.
2006: Jan Jacques Michiels; Zwi Berneman; Wilfried Schroyens; Peter J Koudstaal; Jan Lindemans; Huub H D M van Vliet
Platelet-mediated thrombotic complications in patients with ET: Reversal by aspirin, platelet reduction, and not by coumadin.
Blood cells, molecules & diseases 2006;36(2):199-205.
2005: Jan Jacques Michiels; Alain Gadisseur; Marc van der Planken; Wilfried Schroyens; Marianne De Maeseneer; Jan T Hermsen; Paul H Trienekens; Henk Hoogsteden; Peter M T Pattynama
Screening for deep vein thrombosis and pulmonary embolism in outpatients with suspected DVT or PE by the sequential use of clinical score: a sensitive quantitative D-dimer test and noninvasive diagnostic tools.
Seminars in vascular medicine 2005;5(4):351-64.
2005: Jan Jacques Michiels; Gualtiero Palareti; Philippe de Moerloose
Fibrin D-dimer testing for venous and arterial thrombotic disease.
Seminars in vascular medicine 2005;5(4):311-4.
2005: Jan Jacques Michiels; Alain Gadisseur; Ulrich Budde; Zwi Berneman; Marc van der Planken; Wilfried Schroyens; Ann van de Velde; Huub H D M van Vliet
Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
Seminars in thrombosis and hemostasis 2005;31(5):577-601.
2005: Jan Jacques Michiels; René H M Te Morsche; J B M J Jansen; Joost P H Drenth
Autosomal dominant erythermalgia associated with a novel mutation in the voltage-gated sodium channel alpha subunit Nav1.7.
Archives of neurology 2005;62(10):1587-90.
2005: Ola E Dahl; Jan Jacques Michiels
Ximelagatran as a new oral anticoagulant for thrombosis.
Seminars in vascular medicine 2005;5(3):223-5.
2005: Jan Jacques Michiels; Alain Gadisseur; Marc van der Planken; Wilfried Schroyens; Marianne De Maeseneer; Jan T Hermsen; Paul H Trienekens; Henk Hoogsteden; Peter M T Pattynama
A critical appraisal of non-invasive diagnosis and exclusion of deep vein thrombosis and pulmonary embolism in outpatients with suspected deep vein thrombosis or pulmonary embolism: how many tests do we need?
International angiology : a journal of the International Union of Angiology 2005;24(1):27-39.
2005: Luc F Van Gaal; Jan Jacques Michiels
Obesity, health issues, and cardiovascular disease.
Seminars in vascular medicine 2005;5(1):1-2.
2005: Jan Jacques Michiels; Alain Gadisseur; Marc van der Planken; Wilfried Schroyens; Zwi Berneman; Marianne De Maeseneer; Jan T Hermsen; Paul H Trienekens
Diagnosis of deep vein thrombosis: how many tests do we need?
Acta chirurgica Belgica 2005;105(1):16-25.
2005: Jan Jacques Michiels
Clinical, pathological and molecular features of the chronic myeloproliferative disorders: MPD 2005 and beyond.
Hematology (Amsterdam, Netherlands) 2005;10 Suppl 1():215-23.
2004: Jan Jacques Michiels; Zwi Berneman; Wilfried Schroyens; Jack Kutti; Birgitta Swolin; Börje Ridell; Pagani Fernando; Ulises Zanetto
Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: natural history and diagnostic differentiation from Ph-negative essential thrombocythemia.
Annals of hematology 2004;83(8):504-12.
2004: Jan Jacques Michiels; Zwi N Berneman; Marc van der Planken; Wilfried Schroyens; Ulrich Budde; Huub H D M van Vliet
Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2004;15(4):323-30.
2004: Jan Jacques Michiels; Zwi N Berneman; Wilfried Schroyens; Huub H D M van Vliet
Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera.
Platelets 2004;15(2):67-84.
2004: Jan Jacques Michiels
Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia.
The hematology journal : the official journal of the European Haematology Association / EHA 2004;5(2):93-102.
2003: Jan Jacques Michiels; Wilfried Schroyens; W De Backer; Marc van der Planken; H Hoogsteden; Peter M T Pattynama
Non-invasive exclusion and diagnosis of pulmonary embolism by sequential use of the rapid ELISA D-dimer assay, clinical score and spiral CT.
International angiology : a journal of the International Union of Angiology 2003;22(1):1-14.
2003: Jan Jacques Michiels; Zwi Berneman; Wilfried Schroyens; H van Urk
Aspirin-responsive painful red, blue, black toe, or finger syndrome in polycythemia vera associated with thrombocythemia.
Annals of hematology 2003;82(3):153-9.
2002: Jan Jacques Michiels; Ari Berghout; Wilfried Schroyens; Wilfried De Backer; Henk Hoogsteden; Peter M T Pattynama
The rehabilitation of clinical assessment for the diagnosis of pulmonary embolism.
Seminars in vascular medicine 2002;2(4):345-51.
2002: Jan Jacques Michiels; Juergen Thiele
Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).
International journal of hematology 2002;76(2):133-45.
2002: Jan Jacques Michiels
Low protein Z associated with venous thrombophilia and with ischemic stroke.
Seminars in vascular medicine 2002;2(2):121-4.
2002: Jan Jacques Michiels; Ann van de Velde; Huub H D M van Vliet; Marc van der Planken; Wilfried Schroyens; Zwi Berneman
Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
Seminars in thrombosis and hemostasis 2002;28(2):111-32.
2002: Jan Jacques Michiels; H Kasbergen; R Oudega; F van der Graaf; Marianne De Maeseneer; Marc van der Planken; Wilfried Schroyens
Exclusion and diagnosis of deep vein thrombosis in outpatients by sequential noninvasive tools.
International angiology : a journal of the International Union of Angiology 2002;21(1):9-19.
2001: Jan Jacques Michiels; Ulrich Budde; Marc van der Planken; Huub H D M van Vliet; Wilfried Schroyens; Zwi Berneman
Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.
Best practice & research. Clinical haematology 2001;14(2):401-36.
2001: Katinka Schatteman; Filip Goossens; Judith Leurs; Robert Verkerk; Simon Scharpé; Jan Jacques Michiels; Dirk F Hendriks
Carboxypeptidase U at the interface between coagulation and fibrinolysis.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2001;7(2):93-101.
2001: Jan Jacques Michiels; Wilfried Schroyens; Zwi Berneman; Marc van der Planken
Acquired von Willebrand syndrome type 1 in hypothyroidism: reversal after treatment with thyroxine.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2001;7(2):113-5.
2001: Jan Jacques Michiels; Wilfried Schroyens; Marc van der Planken; Zwi Berneman
Acquired von Willebrand syndrome in systemic lupus erythematodes.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2001;7(2):106-12.
2000: Jan Jacques Michiels; G Freyburger; F van der Graaf; M Janssen; WJ Oortwijn; Edwin J.R. van Beek
Strategies for the safe and effective exclusion and diagnosis of deep vein thrombosis by the sequential use of clinical score, D-dimer testing, and compression ultrasonography.
Seminars in thrombosis and hemostasis 2000;26(6):657-67.
1999: Jan Jacques Michiels; J van der Meer; K Hamulyàk; H Wollersheim; WJ Oortwijn; R Naaborg
Diagnosis of deep vein thrombosis by the use of a rapid ELISA D-dimer test, CUS, and a clinical model: a cost-effectiveness analysis.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 1999;5(4):219-21.
1999: K Hamulyàk; F van der Graaf; M C Janssen; P de Moerloose; Jan Jacques Michiels
Exclusion of deep vein thrombosis with rapid ELISA D-dimer testing: from theory to daily practice.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 1999;5(4):216-9.
1999: Jan Jacques Michiels; WJ Oortwijn; R Naaborg
Exclusion and diagnosis of deep vein thrombosis by a rapid ELISA D-dimer test, compression ultrasonography, and a simple clinical model.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 1999;5(3):171-80.
1999: Perry van Genderen; FJ Prins; Jan Jacques Michiels; K Schrör
Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: a rationale for the use of low-dose aspirin as an antithrombotic agent.
British journal of haematology 1999;104(3):438-41.
1998: Perry van Genderen; Jan Jacques Michiels
Acquired von Willebrand disease.
Baillière's clinical haematology 1998;11(2):319-30.
1997: Perry van Genderen; FJ Prins; I S Lucas; D van de Moesdijk; Huub H D M van Vliet; R van Strik; Jan Jacques Michiels
Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet count.
British journal of haematology 1997;99(4):832-6.
1997: Perry van Genderen; Huub H D M van Vliet; FJ Prins; D van de Moesdijk; R van Strik; Freek Jan Zijlstra; Ulrich Budde; Jan Jacques Michiels
Excessive prolongation of the bleeding time by aspirin in essential thrombocythemia is related to a decrease of large von Willebrand factor multimers in plasma.
Annals of hematology 1997;75(5-6):215-20.
1997: Perry van Genderen; P G Mulder; M Waleboer; D van de Moesdijk; Jan Jacques Michiels
Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin.
British journal of haematology 1997;97(1):179-84.
1997: Mies C Kappers-Klunne; D M Boon; W C Hop; Jan Jacques Michiels; J Stibbe; C van der Zwaan; Peter J Koudstaal; Huub H D M van Vliet
Heparin-induced thrombocytopenia and thrombosis: a prospective analysis of the incidence in patients with heart and cerebrovascular diseases.
British journal of haematology 1997;96(3):442-6.
1996: Perry van Genderen; H Leenknegt; Jan Jacques Michiels; Ulrich Budde
Acquired von Willebrand disease in myeloproliferative disorders.
Leukemia & lymphoma 1996;22 Suppl 1():79-82.
1996: Jan Jacques Michiels; Perry van Genderen; P H Jansen; Peter J Koudstaal
Atypical transient ischemic attacks in thrombocythemia of various myeloproliferative disorders.
Leukemia & lymphoma 1996;22 Suppl 1():65-70.
1996: Jan Jacques Michiels; Perry van Genderen; Jan Lindemans; Huub H D M van Vliet
Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia.
Leukemia & lymphoma 1996;22 Suppl 1():47-56.
1996: Jan Jacques Michiels
The myeloproliferative disorders. An historical appraisal and personal experiences.
Leukemia & lymphoma 1996;22 Suppl 1():1-14.
1996: Perry van Genderen; I S Lucas; R van Strik; VD Vuzevski; F J Prins; Huub H D M van Vliet; Jan Jacques Michiels
Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation.
Thrombosis and haemostasis 1996;76(3):333-8.
1996: Perry van Genderen; Ulrich Budde; Jan Jacques Michiels; R van Strik; Huub H D M van Vliet
The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count.
British journal of haematology 1996;93(4):962-5.
1996: D M Boon; Jan Jacques Michiels; H L Tanghe; M C Kappers-Klunne
Heparin-induced thrombocytopenia with multiple cerebral infarctions simulating thrombotic thrombocytopenic purpura. A case report.
Angiology 1996;47(4):407-11.
1996: H Engel; L Zwang; Huub H D M van Vliet; Jan Jacques Michiels; J Stibbe; Jan Lindemans
Phenotyping and genotyping of coagulation factor V Leiden.
Thrombosis and haemostasis 1996;75(2):267-9.
1995: Jan Jacques Michiels; L van der Luit; Huub H D M van Vliet; K Jochmans; Willy Lissens
Nonsense mutation Arg197stop in a Dutch family with type 1 hereditary antithrombin (AT) deficiency causing thrombophilia.
Thrombosis research 1995;78(3):251-4.
1995: Perry van Genderen; W Terpstra; Jan Jacques Michiels; L Kapteijn; Huub H D M van Vliet
High-dose intravenous immunoglobulin delays clearance of von Willebrand factor in acquired von Willebrand disease.
Thrombosis and haemostasis 1995;73(5):891-2.
1995: D M Boon; M C Kappers-Klunne; Jan Jacques Michiels; J Stibbe; Huub H D M van Vliet
Heparin-induced thrombocytopenia and thrombosis: a potential fatal complication in a routine treatment.
The Netherlands journal of medicine 1995;46(3):146-52.
1995: Perry van Genderen; Jan Jacques Michiels; R van Strik; Jan Lindemans; Huub H D M van Vliet
Platelet consumption in thrombocythemia complicated by erythromelalgia: reversal by aspirin.
Thrombosis and haemostasis 1995;73(2):210-4.
1995: Jan Jacques Michiels; J P Drenth; Perry van Genderen
Classification and diagnosis of erythromelalgia and erythermalgia.
International journal of dermatology 1995;34(2):97-100.
1994: K Jochmans; Willy Lissens; T Yin; Jan Jacques Michiels; L van der Luit; K Peerlinck; Marc De Waele; I Liebaers
Molecular basis for type 1 antithrombin deficiency: identification of two novel point mutations and evidence for a de novo splice site mutation.
Blood 1994;84(11):3742-8.
1994: swibertus rudolfus poort; Jan Jacques Michiels; P H Reitsma; R M Bertina
Homozygosity for a novel missense mutation in the prothrombin gene causing a severe bleeding disorder.
Thrombosis and haemostasis 1994;72(6):819-24.
1994: Perry van Genderen; D N Papatsonis; Jan Jacques Michiels; J J Wielenga; J Stibbe; F J Huikeshoven
High-dose intravenous gammaglobulin therapy for acquired von Willebrand disease.
Postgraduate medical journal 1994;70(830):916-20.
1994: Perry van Genderen; Tom Vink; Jan Jacques Michiels; M B van 't Veer; Jan J Sixma; Huub H D M van Vliet
Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen.
Blood 1994;84(10):3378-84.
1994: D M Boon; Jan Jacques Michiels; J Stibbe; Huub H D M van Vliet; M C Kappers-Klunne
Heparin-induced thrombocytopenia and antithrombotic therapy.
Lancet 1994;344(8932):1296.
1994: Perry van Genderen; Jan Jacques Michiels; S C van der Poel-van de Luytgaarde; Huub H D M van Vliet
Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count.
Annals of hematology 1994;69(2):81-4.
1994: Perry van Genderen; Jan Jacques Michiels
Arterial thrombophilia in primary thrombocythemia. A case report.
Angiology 1994;45(6):485-8.
1994: J P Drenth; Perry van Genderen; Jan Jacques Michiels
Thrombocythemic erythromelalgia, primary erythermalgia, and secondary erythermalgia: three distinct clinicopathologic entities.
Angiology 1994;45(6):451-3.
1994: Jan Jacques Michiels; J P Drenth
Erythromelalgia and erythermalgia: lumpers and splitters.
International journal of dermatology 1994;33(6):412-3.
1994: J P Drenth; Jan Jacques Michiels
Erythromelalgia and erythermalgia: diagnostic differentiation.
International journal of dermatology 1994;33(6):393-7.
1994: Jan Jacques Michiels; Perry van Genderen; Huub H D M van Vliet
Erythromelalgia and arterial thrombophilia in thrombocythemia.
Annals of the New York Academy of Sciences 1994;714():318-21.
1994: Perry van Genderen; Jan Jacques Michiels
Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia.
Presse médicale (Paris, France : 1983) 1994;23(2):73-7.
1994: Perry van Genderen; Jan Jacques Michiels; J J Bakker; M B van 't Veer
Effectiveness of high-dose intravenous gamma globulin therapy in acquired von Willebrand's disease.
Vox sanguinis 1994;67(1):14-7.
1993: Perry van Genderen; Jan Jacques Michiels
Primary thrombocythemia: diagnosis, clinical manifestations and management.
Annals of hematology 1993;67(2):57-62.
1993: Jan Jacques Michiels; Peter J Koudstaal; A H Mulder; Huub H D M van Vliet
Transient neurologic and ocular manifestations in primary thrombocythemia.
Neurology 1993;43(6):1107-10.
1993: Perry van Genderen; Jan Jacques Michiels; J P Drenth
Hereditary erythermalgia and acquired erythromelalgia.
American journal of medical genetics 1993;45(4):530-2.
1993: Jan Jacques Michiels
Erythroleukemia and myelodysplastic syndromes: an historical appraisal and a personal view.
Leukemia & lymphoma 1993;9(1-2):27-34.
1993: J P Drenth; Jan Jacques Michiels; Theodoor Van Joost; VD Vuzevski
Secondary erythermalgia in systemic lupus erythematosus; [comment].
The Journal of rheumatology 1993;20(1):144-6.
1992: J P Drenth; Jan Jacques Michiels; Theodoor Van Joost; VD Vuzevski
Verapamil-induced secondary erythermalgia.
The British journal of dermatology 1992;127(3):292-4.
1992: Jan Jacques Michiels
Multiple myeloma: prognostic factors and treatment modalities.
The Netherlands journal of medicine 1992;40(5-6):254-70.
1992: Jan Jacques Michiels; F J ten Kate
Erythromelalgia in thrombocythemia of various myeloproliferative disorders.
American journal of hematology 1992;39(2):131-6.
1991: M G Scheffer; Jan Jacques Michiels; Maarten L Simoons; Jos R T C Roelandt
Thrombocythemia and coronary artery disease.
American heart journal 1991;122(2):573-6.
1990: R W Wulkan; Jan Jacques Michiels
Pseudohyperkalaemia in thrombocythaemia.
Journal of clinical chemistry and clinical biochemistry. Zeitschrift für klinische Chemie und klinische Biochemie 1990;28(7):489-91.
1990: Jan Jacques Michiels; Theodoor Van Joost
Erythromelalgia and thrombocythemia: a causal relation.
Journal of the American Academy of Dermatology 1990;22(1):107-11.
1989: Jan Jacques Michiels; Theodoor Van Joost; VD Vuzevski
Idiopathic erythermalgia: a congenital disorder.
Journal of the American Academy of Dermatology 1989;21(5 Pt 2):1128-30.
1988: Jan Jacques Michiels; H J Adriaansen; Anne Hagemeijer; Herbert Hooijkaas; Jacques J M van Dongen; J Abels
TdT positive B-cell acute lymphoblastic leukaemia (B-ALL) without Burkitt characteristics.
British journal of haematology 1988;68(4):423-6.
1987: Jan Jacques Michiels; M E Prins; A Hagermeijer; P Brederoo; J van der Meulen; Huub H D M van Vliet; J Abels
Philadelphia chromosome-positive thrombocythemia and megakaryoblast leukemia.
American journal of clinical pathology 1987;88(5):645-52.
1987: Jan Jacques Michiels; J Stibbe; R Bertina; A Broekmans
Effectiveness of long term oral anticoagulation treatment in preventing venous thrombosis in hereditary protein S deficiency.
British medical journal (Clinical research ed.) 1987;295(6599):641-3.
1985: Jan Jacques Michiels; J Abels; J Steketee; Huub H D M van Vliet; VD Vuzevski
Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia.
Annals of internal medicine 1985;102(4):466-71.
1984: Jan Jacques Michiels; J Stibbe; E Vellenga; Huub H D M van Vliet
Prophylaxis of thrombosis in antithrombin III-deficient women during pregnancy and delivery.
European journal of obstetrics, gynecology, and reproductive biology 1984;18(3):149-53.
1984: J J van Dongen; H Hooijkaas; Jan Jacques Michiels; G Grosveld; A de Klein; T H van der Kwast; M E Prins; J Abels; A Hagemeijer
Richter's syndrome with different immunoglobulin light chains and different heavy chain gene rearrangements.
Blood 1984;64(2):571-5.